The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally.
"That would apply to women's health in general, and then specifically and acutely to menopause in particular."
From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed.
The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study.
Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.
Persons:
Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen
Organizations:
McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners
Locations:
U.S, Tokyo